TWI908113B - 抗tigit抗體及其用途 - Google Patents

抗tigit抗體及其用途

Info

Publication number
TWI908113B
TWI908113B TW113120895A TW113120895A TWI908113B TW I908113 B TWI908113 B TW I908113B TW 113120895 A TW113120895 A TW 113120895A TW 113120895 A TW113120895 A TW 113120895A TW I908113 B TWI908113 B TW I908113B
Authority
TW
Taiwan
Prior art keywords
antibody
cancer
antigen
tigit
seq
Prior art date
Application number
TW113120895A
Other languages
English (en)
Chinese (zh)
Other versions
TW202448954A (zh
Inventor
楊寶田
鄭勇
羅芳芳
梁忠爽
陳海清
聶思惟
繼杰 顧
Original Assignee
大陸商上海藥明生物技術有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商上海藥明生物技術有限公司 filed Critical 大陸商上海藥明生物技術有限公司
Publication of TW202448954A publication Critical patent/TW202448954A/zh
Application granted granted Critical
Publication of TWI908113B publication Critical patent/TWI908113B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW113120895A 2023-06-06 2024-06-05 抗tigit抗體及其用途 TWI908113B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2023098574 2023-06-06
WOPCT/CN2023/098574 2023-06-06

Publications (2)

Publication Number Publication Date
TW202448954A TW202448954A (zh) 2024-12-16
TWI908113B true TWI908113B (zh) 2025-12-11

Family

ID=93795086

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113120895A TWI908113B (zh) 2023-06-06 2024-06-05 抗tigit抗體及其用途

Country Status (8)

Country Link
EP (1) EP4724493A1 (fr)
KR (1) KR20260036407A (fr)
CN (1) CN121620534A (fr)
AU (1) AU2024286100A1 (fr)
IL (1) IL325132A (fr)
MX (1) MX2025014705A (fr)
TW (1) TWI908113B (fr)
WO (1) WO2024251140A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609813A (zh) * 2014-08-19 2016-03-16 默沙東藥廠 抗ｔｉｇｉｔ抗體

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6180663B2 (ja) * 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
LT3618863T (lt) * 2017-05-01 2023-10-10 Agenus Inc. Anti-tigit antikūnai ir jų panaudojimo būdai
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
CA3146986A1 (fr) * 2019-07-15 2021-01-21 Shanghai Junshi Biosciences Co., Ltd. Anticorps anti-tigit et leur application
WO2021093849A1 (fr) * 2019-11-14 2021-05-20 Wuxi Biologics (Shanghai) Co., Ltd. Nouvel anticorps dirigé contre tigit
CN115466327B (zh) * 2021-06-10 2025-07-08 北京天广实生物技术股份有限公司 结合tigit的抗体及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609813A (zh) * 2014-08-19 2016-03-16 默沙東藥廠 抗ｔｉｇｉｔ抗體

Also Published As

Publication number Publication date
EP4724493A1 (fr) 2026-04-15
IL325132A (en) 2026-02-01
AU2024286100A1 (en) 2026-01-22
WO2024251140A1 (fr) 2024-12-12
KR20260036407A (ko) 2026-03-16
MX2025014705A (es) 2026-03-02
CN121620534A (zh) 2026-03-06
TW202448954A (zh) 2024-12-16

Similar Documents

Publication Publication Date Title
CN110204614B (zh) 抗人lag-3单克隆抗体及其制备方法和用途
TWI831778B (zh) 抗ox40的全人抗體及其製備方法和用途
CN114599681B (zh) 新型抗cd47抗体及其用途
US20240352153A1 (en) Pharmaceutical composition and use
JP2024029261A (ja) 新規の抗ｐｄ－１抗体
JP7445752B2 (ja) 新規の抗ｐｄ－ｌ１抗体
CN112552411B (zh) 新型抗pd-l1/抗lag-3双特异性抗体及其用途
CN113195538B (zh) 抗tim-3抗体及其用途
TWI908113B (zh) 抗tigit抗體及其用途
WO2024251161A1 (fr) Anticorps anti-tigit x pvrig et leurs utilisations
WO2024251160A1 (fr) Anticorps anti-pvrig et leurs utilisations
US20250215109A1 (en) Anti-her2/anti-cd47 molecules and uses thereof
TW202513589A (zh) 抗TIGIT x PVRIG抗體及其應用
TW202523694A (zh) 抗muc16抗體及其用途
HK40115142A (zh) 抗her2/抗cd47分子及其用途
HK40076079A (zh) 抗人lag-3抗体及其用途
TW202430210A (zh) 用於治療癌症之btn3a活化抗體、bcl2抑制劑及去甲基化劑之組合